Your browser doesn't support javascript.
loading
EULAR definition of difficult-to-treat rheumatoid arthritis.
Nagy, György; Roodenrijs, Nadia Mt; Welsing, Paco Mj; Kedves, Melinda; Hamar, Attila; van der Goes, Marlies C; Kent, Alison; Bakkers, Margot; Blaas, Etienne; Senolt, Ladislav; Szekanecz, Zoltan; Choy, Ernest; Dougados, Maxime; Jacobs, Johannes Wg; Geenen, Rinie; Bijlsma, Hans Wj; Zink, Angela; Aletaha, Daniel; Schoneveld, Leonard; van Riel, Piet; Gutermann, Loriane; Prior, Yeliz; Nikiphorou, Elena; Ferraccioli, Gianfranco; Schett, Georg; Hyrich, Kimme L; Mueller-Ladner, Ulf; Buch, Maya H; McInnes, Iain B; van der Heijde, Désirée; van Laar, Jacob M.
Afiliação
  • Nagy G; Department of Rheumatology, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary nagy.gyorgy2@med.semmelweis-univ.hu.
  • Roodenrijs NMT; Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary.
  • Welsing PM; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Kedves M; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Hamar A; Department of Rheumatology, Bács-Kiskun County Hospital, Kecskemét, Hungary.
  • van der Goes MC; Department of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Kent A; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Bakkers M; Department of Rheumatology, Meander Medical Center, Amersfoort, the Netherlands.
  • Blaas E; Salisbury Foundation Trust NHS Hospital, Wiltshire, UK.
  • Senolt L; EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (PARE), Zurich, Switzerland.
  • Szekanecz Z; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Choy E; Department of Rheumatology, 1st Faculty of Medicine, Charles University and Institute of Rheumatology, Prague, Czech Republic.
  • Dougados M; Department of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Jacobs JW; CREATE Centre, Section of Rheumatology, School of Medicine, Division of Infection and Immunity, Cardiff University, Cardiff, UK.
  • Geenen R; Université de Paris Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité, Paris, France.
  • Bijlsma HW; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Zink A; Department of Psychology, Utrecht University, Utrecht, the Netherlands.
  • Aletaha D; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Schoneveld L; Epidemiology Unit, German Rheumatism Research Centre, and Rheumatology, Charité, University Medicine, Berlin, Germany.
  • van Riel P; Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria.
  • Gutermann L; Department of Rheumatology, Bravis Hospital, Roosendaal, the Netherlands.
  • Prior Y; Department of Rheumatic Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.
  • Nikiphorou E; Department of Pharmacy, Paris Descartes University, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Paris, France.
  • Ferraccioli G; School of Health and Society, Centre for Health Sciences Research, University of Salford, Salford, UK.
  • Schett G; Centre for Rheumatic Diseases, King's College London, London, UK.
  • Hyrich KL; School of Medicine, Catholic University of the Sacred Heart, Rome, Italy.
  • Mueller-Ladner U; Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University of Erlangen-Nuremberg and Universitatsklinikum Erlangen, Erlangen, Germany.
  • Buch MH; NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
  • McInnes IB; Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK.
  • van der Heijde D; Department of Rheumatology and Clinical Immunology, Justus-Liebig University Giessen, Kerckhoff Clinic Bad Nauheim, Bad Nauheim, Germany.
  • van Laar JM; NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
Ann Rheum Dis ; 80(1): 31-35, 2021 01.
Article em En | MEDLINE | ID: mdl-33004335
ABSTRACT

BACKGROUND:

Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be considered to have 'difficult-to-treat RA'. However, uniform terminology and an appropriate definition are lacking.

OBJECTIVE:

The Task Force in charge of the "Development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis" aims to create recommendations for this underserved patient group. Herein, we present the definition of difficult-to-treat RA, as the first step.

METHODS:

The Steering Committee drafted a definition with suggested terminology based on an international survey among rheumatologists. This was discussed and amended by the Task Force, including rheumatologists, nurses, health professionals and patients, at a face-to-face meeting until sufficient agreement was reached (assessed through voting).

RESULTS:

The following three criteria were agreed by all Task Force members as mandatory elements of the definition of difficult-to-treat RA (1) Treatment according to European League Against Rheumatism (EULAR) recommendation and failure of ≥2 biological disease-modifying antirheumatic drugs (DMARDs)/targeted synthetic DMARDs (with different mechanisms of action) after failing conventional synthetic DMARD therapy (unless contraindicated); (2) presence of at least one of the following at least moderate disease activity; signs and/or symptoms suggestive of active disease; inability to taper glucocorticoid treatment; rapid radiographic progression; RA symptoms that are causing a reduction in quality of life; and (3) the management of signs and/or symptoms is perceived as problematic by the rheumatologist and/or the patient.

CONCLUSIONS:

The proposed EULAR definition for difficult-to-treat RA can be used in clinical practice, clinical trials and can form a basis for future research.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Produtos Biológicos / Antirreumáticos / Glucocorticoides Tipo de estudo: Guideline / Qualitative_research Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Ann Rheum Dis Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Hungria

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Produtos Biológicos / Antirreumáticos / Glucocorticoides Tipo de estudo: Guideline / Qualitative_research Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Ann Rheum Dis Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Hungria